Vincent Enright
About Vincent D. Enright
Vincent D. Enright is an Independent Trustee of GAMCO Global Gold, Natural Resources & Income Trust (GGN), serving on the Board since 2005 and nominated to serve through the 2028 annual meeting. He is Chairman of the Fund’s Audit Committee and ad hoc Proxy Voting Committee and has been designated the Audit Committee Financial Expert; previously Senior Vice President and Chief Financial Officer of KeySpan Corp. (1994–1998). He holds a bachelor’s degree from Fordham University and completed the Advanced Management Program at Harvard University; year of birth 1943.
Past Roles
| Organization | Role | Tenure | Committees/Impact |
|---|---|---|---|
| KeySpan Corp. (public utility) | Senior Vice President & CFO | 1994–1998 | CFO experience in a regulated energy utility context, foundational for audit oversight |
External Roles
| Organization | Role | Tenure | Committees/Impact |
|---|---|---|---|
| Echo Therapeutics, Inc. (therapeutics & diagnostics) | Director | 2008–2014 | Chairman of Compensation Committee; member of Audit Committee |
| The LGL Group, Inc. (diversified manufacturing) | Director | 2011–2014 | Director |
Board Governance
- Independence: Enright is an Independent Trustee under the 1940 Act and not an “interested person” (as defined), with the Board noting independence of non-interested Trustees as of Dec 31, 2024.
- Committee assignments: Chairman, Audit Committee; Chairman, ad hoc Proxy Voting Committee; member of both multi-fund ad hoc Compensation Committees; designated Audit Committee Financial Expert.
- Board leadership: Board has no Chairman; Lead Independent Trustee is James P. Conn.
- Attendance and meetings: Board met four times in FY 2024 and FY 2023; each Trustee attended at least 75% of Board and applicable committee meetings. Audit Committee met two times in FY 2024 and FY 2023.
- Annual meeting attendance: The Fund does not expect Trustees or nominees to attend the annual meeting; no Trustees or nominees attended the May 13, 2024 meeting; 2025 proxy reiterates non‑attendance expectation.
Board and Committee Activity
| Metric | FY 2023 | FY 2024 |
|---|---|---|
| Board meetings held (count) | 4 | 4 |
| Audit Committee meetings (count) | 2 | 2 |
| Attendance compliance (each Trustee) | ≥75% | ≥75% |
Fixed Compensation
Compensation framework for Trustees consists of a cash retainer, per‑meeting fees, and specific chair stipends.
| Component (GGN) | FY 2023 | FY 2024 |
|---|---|---|
| Annual retainer (Independent Trustee) | $15,000 | $15,000 |
| Board meeting fees ($2,000 per meeting × 4) | $8,000 | $8,000 |
| Audit Committee Chair annual fee | $3,000 | $3,000 |
| Committee meeting fees ($1,000 per meeting × Audit 2) | $2,000 | $2,000 |
| Aggregate compensation from GGN (Enright) | $28,000 | $28,000 |
| Aggregate compensation from Fund Complex (Enright) | $218,263 (over 17 portfolios) | $217,637 (over 17 portfolios) |
Notes:
- Fee structure applies to all Independent Trustees; Audit Chair stipend applies to Enright.
- A Trustee may receive a single meeting fee allocated across participating funds for certain multi‑fund meetings.
Performance Compensation
- No equity awards (RSUs/PSUs), options, target/actual bonuses, or performance‑linked metrics for Trustees are disclosed; the compensation framework is cash‑based (retainers, meeting fees, chair stipends).
Other Directorships & Interlocks
| Company | Relationship to Adviser/Affiliates | Role |
|---|---|---|
| Echo Therapeutics, Inc. | Not indicated as affiliated | Former Director; Compensation Chair; Audit Committee member |
| The LGL Group, Inc. | Not indicated as affiliated | Former Director |
- The proxy includes a table of certain affiliated interests for Independent Trustees; Enright is not listed with affiliated interests in that table (others are).
Expertise & Qualifications
- Designated Audit Committee Financial Expert for GGN (Reg S‑K Items 407(d)(5)(ii) and (iii)).
- Senior finance operating experience as CFO of a public utility (KeySpan), relevant for oversight of financial reporting, internal controls, and valuation.
- Education: Bachelor’s, Fordham University; Advanced Management Program, Harvard University.
- Oversees 17 portfolios in the Gabelli Fund Complex, indicating breadth across fund governance.
Equity Ownership
| Holding | As of Dec 31, 2023 | As of Dec 31, 2024 |
|---|---|---|
| Dollar range of equity securities in GGN | A: None | A: None |
| Aggregate dollar range in Fund Complex | E: Over $100,000 | E: Over $100,000 |
| Shares owned in GGN | 0 Common Shares; <1% of outstanding | 0 Common Shares; <1% of outstanding |
- Section 16(a) compliance: The Fund believes all required ownership filings by Trustees and officers were timely for FY 2023 and FY 2024.
Governance Assessment
- Strengths: Independent Trustee; long‑standing audit leadership; designated financial expert; clear cash‑based fee schedule; consistent Audit Committee engagement (two meetings annually) supporting oversight of financial reporting and auditor independence.
- Alignment signals: No personal GGN share ownership disclosed (0 shares; dollar range “None”), which can be viewed as limited “skin‑in‑the‑game”; conversely, substantial aggregate fund complex holdings and responsibilities indicate broad governance exposure across Gabelli funds.
- Engagement signals: Board and committee attendance met ≥75% threshold; however, trustees (including nominees) did not attend the 2024 annual meeting and are not expected to attend the 2025 meeting, which some governance practitioners view as reduced direct shareholder engagement.
- Potential conflicts/related party exposure: Proxy’s affiliated interests table lists other Independent Trustees with interests in Adviser‑related entities but does not list Enright; no related‑party issues specific to Enright are disclosed. Participation on multi‑fund ad hoc Compensation Committees may create cross‑fund influence over officer compensation, requiring continued transparency and independence safeguards.
RED FLAGS
- No director‑specific red flags (legal proceedings, SEC investigations, related‑party transactions, hedging/pledging) are disclosed for Enright in the proxy.